Literature DB >> 29542038

Taxifolin prevents β-amyloid-induced impairments of synaptic formation and deficits of memory via the inhibition of cytosolic phospholipase A2/prostaglandin E2 content.

Yuanyuan Wang1, Qinwen Wang1, Xiaoming Bao2, Yanfei Ding1, Jieyi Shentu1, Wei Cui1, Xiaowei Chen1, Xiaofei Wei1, Shujun Xu3.   

Abstract

Taxifolin is a potent flavonoid with anti-inflammatory activity. Taxifolin has been reported to decrease the accumulation of β-amyloid (Aβ), and reduce Aβ-induced neurotoxicity. However, the detail molecular mechanism of taxifolin against Aβ-induced neurotoxicity is largely unknown. In this study, we revealed the protective effects and the underlying mechanisms of taxifolin on the impairments of cognitive function and synapse formation induced by soluble Aβ oligomers. Our results showed that taxifolin prevented neuronal cell death in a concentration-dependent manner. The recognition memory in novel object recognition tasks and the spatial memory in Morris water maze tests are significantly lower in the Alzheimer's disease (AD) model mice induced by hippocampal injection of Aβ42. Taxifolin treatment prevented the recognitive and spatial memory deficits of the AD mice. 10 mg/kg taxifolin treatment also significantly prevented the decreased expression levels of PSD 95 induced by Aβ42. Live cell imaging study showed that 2 h pre-treatment of taxifolin prevented the decrease in the number of filopodium and spine induced by Aβ42 oligomers. Aβ42 oligomers significantly increased the production of cytosolic phospholipase A2 (cPLA2), a crucial enzyme of pro-inflammatory mediator, and prostaglandin E2 (PGE2), a neuroinflammatory molecule. Taxifolin significantly reduced the content of cPLA2 and PGE2 induced by Aβ42 both in the primary hippocampal neurons and hippocampal tissues. These results indicated that taxifolin might prevent Aβ42 oligomer-induced synapse and cognitive impairments through decreasing cPLA2 and PGE2. Our study provided novel insights into the cellular mechanisms for the protective effects of taxifolin on AD.

Entities:  

Keywords:  Alzheimer’s disease; Cognitive impairments; Cytosolic phospholipase A2; Prostaglandin E2; Synapse; Taxifolin

Mesh:

Substances:

Year:  2018        PMID: 29542038     DOI: 10.1007/s11011-018-0207-5

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  35 in total

Review 1.  Changes in cognition.

Authors:  Marilyn S Albert
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

Review 2.  Soluble Aβ oligomer production and toxicity.

Authors:  Megan E Larson; Sylvain E Lesné
Journal:  J Neurochem       Date:  2011-11-28       Impact factor: 5.372

Review 3.  Alzheimer's disease.

Authors:  Clive Ballard; Serge Gauthier; Anne Corbett; Carol Brayne; Dag Aarsland; Emma Jones
Journal:  Lancet       Date:  2011-03-01       Impact factor: 79.321

Review 4.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

Review 5.  Role of cytosolic phospholipase A2 in oxidative and inflammatory signaling pathways in different cell types in the central nervous system.

Authors:  Grace Y Sun; Dennis Y Chuang; Yijia Zong; Jinghua Jiang; James C M Lee; Zezong Gu; Agnes Simonyi
Journal:  Mol Neurobiol       Date:  2014-02-27       Impact factor: 5.590

6.  Effects of Aβ exposure on long-term associative memory and its neuronal mechanisms in a defined neuronal network.

Authors:  Lenzie Ford; Michael Crossley; Thomas Williams; Julian R Thorpe; Louise C Serpell; György Kemenes
Journal:  Sci Rep       Date:  2015-05-29       Impact factor: 4.379

7.  Concurrent Treatment with Taxifolin and Cilostazol on the Lowering of β-Amyloid Accumulation and Neurotoxicity via the Suppression of P-JAK2/P-STAT3/NF-κB/BACE1 Signaling Pathways.

Authors:  So Youn Park; Hae Young Kim; Hee Jeong Park; Hwa Kyoung Shin; Ki Whan Hong; Chi Dae Kim
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

8.  Soluble oligomeric amyloid-β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain.

Authors:  Michal Arbel-Ornath; Eloise Hudry; Josiah R Boivin; Tadafumi Hashimoto; Shuko Takeda; Kishore V Kuchibhotla; Steven Hou; Carli R Lattarulo; Arianna M Belcher; Naomi Shakerdge; Pariss B Trujillo; Alona Muzikansky; Rebecca A Betensky; Bradley T Hyman; Brian J Bacskai
Journal:  Mol Neurodegener       Date:  2017-03-21       Impact factor: 14.195

9.  Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy.

Authors:  Satoshi Saito; Yumi Yamamoto; Takakuni Maki; Yorito Hattori; Hideki Ito; Katsuhiko Mizuno; Mariko Harada-Shiba; Raj N Kalaria; Masanori Fukushima; Ryosuke Takahashi; Masafumi Ihara
Journal:  Acta Neuropathol Commun       Date:  2017-04-04       Impact factor: 7.801

10.  The Neuroprotective Effects of Brazilian Green Propolis on Neurodegenerative Damage in Human Neuronal SH-SY5Y Cells.

Authors:  Junjun Ni; Zhou Wu; Jie Meng; Aiqin Zhu; Xin Zhong; Shizheng Wu; Hiroshi Nakanishi
Journal:  Oxid Med Cell Longev       Date:  2017-02-06       Impact factor: 6.543

View more
  7 in total

1.  7-O-Esters of taxifolin with pronounced and overadditive effects in neuroprotection, anti-neuroinflammation, and amelioration of short-term memory impairment in vivo.

Authors:  Sandra Gunesch; Matthias Hoffmann; Carolina Kiermeier; Wolfgang Fischer; Antonio F M Pinto; Tangui Maurice; Pamela Maher; Michael Decker
Journal:  Redox Biol       Date:  2019-11-09       Impact factor: 11.799

Review 2.  Taxifolin: A Potential Therapeutic Agent for Cerebral Amyloid Angiopathy.

Authors:  Satoshi Saito; Masashi Tanaka; Noriko Satoh-Asahara; Roxana Octavia Carare; Masafumi Ihara
Journal:  Front Pharmacol       Date:  2021-02-12       Impact factor: 5.810

3.  Dihydroquercetin ameliorates LPS-induced neuroinflammation and memory deficit.

Authors:  Qadir Alam; Sairam Krishnamurthy
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-02-10

Review 4.  Novel Therapeutic Potentials of Taxifolin for Amyloid-β-associated Neurodegenerative Diseases and Other Diseases: Recent Advances and Future Perspectives.

Authors:  Masashi Tanaka; Satoshi Saito; Takayuki Inoue; Noriko Satoh-Asahara; Masafumi Ihara
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

Review 5.  Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease.

Authors:  Masashi Tanaka; Satoshi Saito; Takayuki Inoue; Noriko Satoh-Asahara; Masafumi Ihara
Journal:  Int J Mol Sci       Date:  2020-03-14       Impact factor: 5.923

Review 6.  Preclinical Research of Dihydromyricetin for Brain Aging and Neurodegenerative Diseases.

Authors:  Hilda Martínez-Coria; Martha X Mendoza-Rojas; Isabel Arrieta-Cruz; Héctor E López-Valdés
Journal:  Front Pharmacol       Date:  2019-11-11       Impact factor: 5.810

7.  Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease.

Authors:  Melanie Ricke-Hoch; Elisabeth Stelling; Lisa Lasswitz; Antonia P Gunesch; Martina Kasten; Francisco J Zapatero-Belinchón; Graham Brogden; Gisa Gerold; Thomas Pietschmann; Virginie Montiel; Jean-Luc Balligand; Federica Facciotti; Emilio Hirsch; Thomas Gausepohl; Husni Elbahesh; Guus F Rimmelzwaan; Anne Höfer; Mark P Kühnel; Danny Jonigk; Julian Eigendorf; Uwe Tegtbur; Lena Mink; Michaela Scherr; Thomas Illig; Axel Schambach; Tobias J Pfeffer; Andres Hilfiker; Axel Haverich; Denise Hilfiker-Kleiner
Journal:  PLoS One       Date:  2021-08-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.